Abstract Congenital melanocytic naevi (CMN) are benign melanocytic proliferations originating from neural crest cells, presenting at birth or in early infancy with variable clinical manifestations and malignancy risks. The incidence of CMN varies in different genders, with a higher prevalence in females but with potentially greater complications in males. Genetic studies have highlighted the pivotal role of mutations in BRAF and NRAS in influencing the size and malignancy risk of CMN. Diagnostic challenges necessitate a systematic approach, including histopathology, molecular profiling, and risk-stratified therapeutic selection. This review synthesizes current knowledge on CMN epidemiology, molecular pathogenesis, diagnostic advancements, and therapeutic strategies. Future directions emphasize longitudinal studies to validate interventions, multidisciplinary collaboration, and biomarker-driven personalized management.
Liu et al. (Wed,) studied this question.